Aptima HPV and Aptima genotype assays for triage of borderline squamous (ASCUS) cytology: CLEAR study

Create PDF

1. Gibson JS. Nucleic acid-based assays for the detection of high-risk human papillomavirus: a technical review. Cancer Cytopathol. 2014;122(9):639–645.
2. U.S. Food and Drug Administration. www.fda.gov. Accessed March 24, 2015.
3. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127(8):946–949.
4. Castle PE, Cuzick J, Stoler MH, et al. Detection of human papillomavirus 16, 18, and 45 in women with ASC-US cytology and the risk of cervical precancer: results from the CLEAR HPV study. Am J Clin Pathol. 2015;143(2):160–167.
5. Stoler MH, Wright TC Jr, Cuzick J, et al. APTIMA HPV assay performance in women with atypical squamous cells of undetermined significance cytology results. Am J Obstet Gynecol. 2013;208(2):144.e1–144.e8.
6. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis. 2015;19(2):91–96.

Dr. Husain is a professor of pathology and Dr. Gibson is a professor of pathology and director of clinical molecular diagnostics, Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando. Dr. Husain is a member of the CAP Cytopathology Committee.